- €14.52m
- €10.72m
- €13.19m
Brief: Biofrontera Announces Initiation Of Two Clinical Studies
Brief: Biofrontera CEO Seeks Early Retirement From Management Board
Brief: Biofrontera Announces Early Repayment Of EIB Loan
Brief: Biofrontera Announces IPO of Biofrontera Inc.
Brief: Biofrontera AG Says It Approves Modification Of US-IPO Of Biofrontera Inc
Brief: Biofrontera AG Receives FDA-Approval Of The Bf-Rhodoled Xl Lamp
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:06 AM
Brief: Biofrontera Approves IPO Of Biofrontera Inc. In USA
Brief: Biofrontera Reports Preliminary Revenues For September
Brief: Biofrontera Reports Preliminary Revenue For The Month Of August 2021
Brief: Biofrontera August Revenue At EUR 1.49 Mln, Up 11%
German stocks - Factors to watch on August 20
Brief: Biofrontera H1 Loss After Tax Widens To EUR 8.9 Million
Brief: Biofrontera Reports Preliminary Revenue For The Month Of July
Brief: Biofrontera To Market Medac's Ameluz And Bf-Rhodoled In Poland
Brief: Biofrontera Inc Files For IPO Of Up To $25 Million
Brief: Biofrontera Reports Preliminary Revenue For The Month Of June 2021
Brief: Biofrontera Provides Update On Clinical Developments
Brief: Biofrontera Q1 EBIT At EUR -3.97 Mln